Figure 4
Relative abundance of N-glycans for each tissue type most altered in cancer. N-glycans with increased relative abundance in cancer (i.e., cancer-associated N-glycans) are outlined in red; N-glycans with decreased relative abundance in cancer (i.e., normal-associated N-glycans) are outlined in green. (A) Bladder (n = 4)—1647.5865 (Hex4dHex1HexNAc4). (B) Breast (n = 7)—1743.5810 (Hex8HexNAc2). (C) Cervix (n = 4)—2539.9037 (Hex7dHex1HexNAc6). (D) Colon (n = 10)—2012.7187 (Hex5dHex1HexNAc5). (E) Esophagus (n = 5)—1460.5020 (Hex5HexNAc3). (F) Gastric (n = 4)—1688.6130 (Hex3dHex1HexNAc5). (G) Kidney (n = 3)—2158.7766 (Hex5dHex2HexNAc5). (H) Liver (n = 4)—933.3170 (Hex3HexNAc2). (I) Lung (n = 10)—2377.8509 (Hex6dHex1HexNAc6). (J) Pancreas (n = 5)—2320.8294 (Hex6dHex2HexNAc5). (K) Prostate (n = 8)—1647.5865 (Hex4dHex1HexNAc4). (L) Sarcoma (n = 4)—1485.5337 (Hex3dHex1HexNAc4). (M) Skin (n = 5)—2539.9037 (Hex8HexNAc2). (N) Thyroid (n = 6)—1911.5859 (Hex5dHex1HexNAc4 + 2Na + SO4). (O) Uterus (n = 3)—1976.6666 (Hex7dHex1HexNAc6).
